Alumis Inc. Common Stock (ALMS) - Stock Analysis
Last updated: Jun 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Deep losses ⢠Rich valuation ALMS has a strong balance sheet and ample liquidity, but heavy ongoing losses, negative cash flow, and a demanding valuation make the stock difficult to justify on fundamentals.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support break ⢠Weak rebounds Support Level: $20.00 Resistance Level: $20.33-$21.60 Over the last month, ALMS has been in a clear downtrend with lower highs and lows, and the break below $20.00 signals weakening support and continued bearish momentum. ŕ´ ŕ´
Sentiment & News
Key News Insights: ⢠Institutional Buying ⢠Phase 3 Data ⢠Mixed Ownership ALMS surged amid strong institutional buying interest and encouraging Phase 3 envudeucitinib psoriasis data, though some investors also trimmed positions during the rally.
AI Summary
ALMS has shifted from a promising biotech to a proof-of-execution story: positive Phase 3 data and a strong cash position reduce near-term survival risk, but heavy burn, single-asset dependence, and weak price action mean the stock likely only rerates if envudeucitinib clearly advances toward approval and differentiated commercialization.
Description
Alumis Inc. is a clinical-stage biopharmaceutical company developing allosteric TYK2 inhibitors to treat autoimmune conditions. Its lead program, ESK-001, is in clinical development for dermatologic, systemic and ocular autoimmune disorders, while A-005 is a CNS-penetrant candidate intended for neuroinflammatory and neurodegenerative indications. The company was incorporated in 2021, renamed from Esker Therapeutics in January 2022, and is based in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 29 | Feb 5 | ALMS | Alumis Inc. Common Stock | Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst. | Closed | -1.9% |
| Jan 7 | Jan 14 | ALMS | Alumis Inc. Common Stock | Selected due to recent Phase 3 clinical trial success on 2026-01-07 driving strong near-term momentum and technical breakout; event-driven upside expected from FDA submission and regulatory catalysts. | Closed | +35.8% |